Arcutis Biotherapeutics, Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Arcutis appointed Rob Scott, MD to its Board of Directors effective October 23, 2026. Dr. Scott is a veteran pharma executive with 40+ years of experience, formerly Chief Medical Officer at AbbVie (2011–2020) overseeing ~40 molecular entities and 14 major regulatory approvals including Skyrizi and Rinvoq. No financial terms, share grants, or board seat compensation disclosed.
Why this rating
Board appointment of external advisor; no deal, capital event, or strategic pivot. Talent reinforcement is routine governance; material only if product approval or major contract followed.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.